Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

December 18, 2023

https://www.globenewswire.com/news-release/2023/12/18/2797845/0/en/Nexalin-Technology-Reports-Significant-Positive-Results-of-Clinical-Study-Supporting-the-Therapeutic-Benefits-of-its-Gen-2-15-Milliamp-Neurostimulation-Device-on-Treatment-Resistan.html

HOUSTON, TEXAS, Dec. 18, 2023 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq:NXL; NXLIW) today reported the results of a study in patients with treatment-resistant depression (TRD), concerning the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA) neurostimulation device, which indicated a substantial and statistically significant benefit in patients.

Read more at globenewswire.com

Related news for (NXL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.